Immediate Impact
56 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut
2025 Standout
Works of Francesco Amati being referenced
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis
2022
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Francesco Amati | 379 | 216 | 110 | 48 | 716 | |
| Hyun Jung Kim | 300 | 266 | 118 | 57 | 820 | |
| Myung Goo Lee | 368 | 193 | 114 | 58 | 786 | |
| Jee Youn Oh | 248 | 177 | 171 | 67 | 623 | |
| A. Pines | 345 | 286 | 137 | 85 | 766 | |
| Giovanni Puglisi | 341 | 144 | 62 | 25 | 714 | |
| Daniel Drömann | 306 | 100 | 88 | 50 | 753 | |
| C Leung | 192 | 160 | 74 | 26 | 737 | |
| Andrew Fretzayas | 270 | 153 | 82 | 53 | 685 | |
| Shigeo Hanada | 231 | 326 | 190 | 44 | 836 | |
| Jihong Dai | 341 | 176 | 62 | 62 | 760 |
All Works
Login with ORCID to disown or claim papers
Loading papers...